免疫球蛋白替代与预防性抗生素治疗血液恶性瘤的二次性低血糖球蛋白血症
Zoe K McQuilten1,2, Robert Weinkove3,4,5, Le Thi Phuong Thao1
1School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
Blood advances
|April 9, 2024
概括
这项研究发现,免疫球蛋白替代剂和预防性抗生素在预防患有低血糖球蛋白血症的患者感染方面同样有效. 这两种治疗方法在随机可行性试验中表现出相似的结果,支持进一步的研究.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 预防传染病 预防传染病
背景情况:
- 在血液性恶性瘤中,二次性低麦球蛋白血症会增加感染风险.
- 免疫球蛋白替代和预防性抗生素是标准的,但无与伦比的感染预防策略.
- 需要在这个患者群体中直接比较这些干预措施.
研究的目的:
- 进行一项随机对照可行性试验,比较免疫球蛋白替代与预防性抗生素.
- 通过评估患者的坚持和结果,评估更大规模的第三期试验的可行性.
- 主要结局:在12个月后,在分配治疗中生存的患者比例.
主要方法:
- 在7家医院 (澳大利亚/新西兰) 进行随机对照可行性试验.
- 招募了患有二次性低血和感染史或低IgG水平的患者.
- 随机 1:2 给静脉注射免疫球蛋白 (0.4 g/kg/4 周) 或每日抗生素 (三甲-硫甲醇/多西环素) 12 个月.
主要成果:
- 63名患者随机选择 (42种抗生素,21种免疫球蛋白).
- 分配治疗的12个月生存率:76% (免疫球蛋白) 和71% (抗生素) (P=.77).
- 在两组之间,主要感染和与治疗相关的不良事件的发病率相似.
结论:
- 免疫球蛋白替代剂和预防性抗生素在预防感染方面表现出类似的可行性和有效性.
- 结果支持将其推向第三阶段试验,以进行最终比较.
- 这两种策略似乎都是可行的,用于管理二次性低胺球蛋白血症的感染风险.
更多相关视频
09:57Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
Published on: February 14, 2011
11.9K
08:52Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
Published on: May 27, 2011
17.2K
相关概念视频
Humoral Immune Responses
72.7K
Overview
72.7K
Immunodeficiency Diseases
936
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
There are three main causes of immunodeficiency...
936
Immunological Memory
602
Immunological memory, a pivotal pillar of the adaptive immune system, is responsible for the body's ability to remember and respond more swiftly and effectively to previously encountered pathogens. This remarkable feature is what makes vaccines so effective in preventing diseases.
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature...
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature...
602
Development of Immunocompetence
305
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
305
Bone Marrow Sampling and Transplants
327
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
327
Hybridoma Technology
14.7K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.7K
